Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance
Find Stocks Now

AI-Powered Real Estate Marketplace Nobul AI To Acquire Medical-Diagnostics Company Check-Cap

Published 26/03/2024, 13:13
© Reuters.  AI-Powered Real Estate Marketplace Nobul AI To Acquire Medical-Diagnostics Company Check-Cap

Benzinga - by Vandana Singh, Benzinga Editor.

Check-Cap Ltd (NASDAQ:CHEK) shares are trading higher after Nobul AI Corp, on Monday, agreed to acquire Check-Cap, under which the shareholders of Nobul will become the majority holders of the combined company.

If completed, the business combination will create a public company headquartered in Toronto, Canada, focused on an AI-driven fintech marketplace and buying and AI-enabling traditional companies to generate higher returns for their shareholders.

In connection with the transaction, the combined company will apply for listing on the NASDAQ and TSX.

The executive team of Nobul will serve as the executive team of the combined company, led by Regan McGee, Nobul’s Founder, Chief Executive Officer, and Chairman.

“Following a comprehensive and thorough review of strategic alternatives, Check-Cap’s Board of Directors concluded that the proposed transaction with Nobul is in the best interest of our shareholders. We intend to hold a special meeting of Check-Cap shareholders in the coming months to vote on this business combination,” said Paul Medeiros, Chairman of the Board of Directors of Check-Cap.

“The proposed business combination with Check-Cap is expected to be a transformative step forward in the execution of our mission to deliver value to our shareholders. Nobul has a proven track record of successful M&A and PE transactions, and this merger will give us a platform to pursue many more of these opportunistic transactions as a public company,” stated Mr. McGee.

Nobul is an AI-driven fintech company offering a category-leading technology solution for home buyers and sellers.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Check-Cap is a clinical-stage medical diagnostics company aiming to redefine colorectal cancer (CRC) screening by introducing C-Scan, a preparation-free screening test to detect polyps before they may transform into colorectal cancer and enable early intervention and cancer prevention.

C-Scan is an investigational device and is not available for sale in the United States.

Price Action: CHEK shares are up 36.9% at $2.69 during the premarket session on the last check Tuesday.

Photo via Shutterstock

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Read the original article on Benzinga

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.